On August 5, TRANSTHERA-B rose 8.83% in regular trading, trading at 12.64 HKD/share, with turnover of approximately 84.27 million HKD, extending the strong rebound from the previous session.

On the news front, the Hong Kong-listed innovative drug sector has been collectively strengthening in recent days, with southbound capital continuously adding positions in innovative drug targets and foreign capital also allocating to the sector. At the company level, TRANSTHERA-B has been intensively repurchasing H shares since July, accumulating 718,000 shares bought back during the month for a total expenditure exceeding 7 million HKD, signaling management confidence in the company's intrinsic value. Additionally, on July 24 the company granted approximately 5.259 million H share incentives to 67 employees, including 2.817 million share awards and 2.442 million share options, further aligning core team interests with shareholders.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)